Novartis AG · SIX:NOVN

Novartis — Investor Presentation (November 2026)

42 slides from Novartis's investor presentation, Nov 19, 2026

  1. Slide 1: Meet Novartis Management

    Vas Narasimhan, CEO Investor Event London, November 19, 2026 Meet Novartis Management

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potential,” “expected,” “will,” “plan,” “pipeline,” “outlook,” “confident,” or similar express

  3. Slide 3: Novartis has consistently delivered strong sales growth and core margin expansion

    Novartis has consistently delivered strong sales growth and core margin expansion Net sales CAGR Core Oplnc1 CAGR Core margin1 bps cc +8% +15% +1,070 USD bn, % cc1 USD bn, % cc1 % +8% +14% 40.1 +12% +22% 38.7 +7% +10% +5% +18% 36.0 39.5 35.1 +12% +10% 33.9 12.8 32.4 2020 2021 2022 2023 2024 2025 202

  4. Slide 4: Record free cash flow and rising ROIC reflect our strong performance and balance sheet discipline

    Record free cash flow and rising ROIC reflect our strong performance and balance sheet discipline Free cash flow1 Return on invested capital2 USD bn 17.6 ~19% 16.3 ~17% 13.2 14.0 12.1 ~12% ~8% 2022 2023 2024 2025 9M 2026 2022 2023 2024 2025 28.7% 29.0% 32.3% 32.3% 33.3% As % of sales Figures for con

  5. Slide 5: We have delivered TSR performance ahead of peer median

    We have delivered TSR performance ahead of peer median Novartis total shareholder return1 10-year Jan 1, 2017 – Nov 15, 2026 Peer median 275% Median 207% 5-year Jan 1, 2022 – Nov 15, 2026 Peer median 131% Median 57% 3-year Jan 1, 2024 – Nov 15, 2026 Peer median 75% Median 50% 1. As per Bloomberg; ba

  6. Slide 6: Our strategy remains consistent as we pursue our long-term ambition

    Our strategy remains consistent as we pursue our long-term ambition Deliver high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches Focus Priorities Execution 4 core Therapeutic areas Accelerate growth Strengthen Deliver

  7. Slide 7: We maintain our shareholder-friendly capital allocation strategy

    We maintain our shareholder-friendly capital allocation strategy Total capital deployment 2016 to September 30, 2026 Investing in the business Returning capital to shareholders USD Investments in Consistently growing organic business annual dividend 104bn USD Core R&D1 and CapEx Substantial cash 140

  8. Slide 8: In 2026, we expect to grow through the largest LOE impact in our history

    In 2026, we expect to grow through the largest LOE impact in our history, driven by our priority brands and launches Significant LoE impacts1 Growth vs. prior year in cc2 2012 Sales +4% Core OpInc1 +10% 2016 +1% in line vs. PY 2023 -5% -14% 2026 Q1 2026 Q2 2026 Q3 2026 Q1 2026 Q2 2026 Q3 2026 2026 g

  9. Slide 9: Over the mid-term, we expect net sales to grow +5% cc CAGR 2026-2031

    Over the mid-term, we expect net sales to grow +5% cc CAGR 2026-2031 and core margin to reach 40%+ by 2029 Expected, barring unforeseen events Net 2026–2031 sales expected to grow Core Core margin1 expected to return to sales margin +5% cc1 CAGR 40%+ by 2029 1. Core results and constant currencies (

  10. Slide 10: In-market assets expected to more than offset generic erosion, with pipeline adding upside

    In-market assets are expected to more than offset generic erosion, with our probabilized pipeline adding further upside Illustrative net sales, cc1 USD bn +5% CAGR Mainly ianalumab Ac-PSMA-617 del-brax del-desiran Mainly Mainly pelabresib Cosentyx Rhapsido/remibrutinib abelacimab Entresto Leqvio4 Ja

  11. Slide 11: In-market assets with USD 3-10bn peak sales potential

    9 in-market assets with USD 3-10bn peak sales potential, including upgrades across 3 brands Most with issued US patent protection throughout the 2030s3 Upgrade vs. previous peak sales guidance 3 remibrutinib2 Peak sales1 Peak sales1 Peak sales1 Peak sales1 Peak sales1 Peak sales1 Peak sales1 Peak sa

  12. Slide 12: Our commercial organizations continue to drive strong execution across US and International markets

    Our commercial organizations continue to drive strong execution across US and International markets Novartis US select brands (% in NBRx or NBRx growth) Novartis ranking in International markets 2026 YTD 65% Share, leader in early breast cancer1 46% Share, leader in HS2, all lines #2 China7 CSU shar

  13. Slide 13: 10 late-stage assets with multi-billion peak sales guidance

    10 late-stage assets with multi-billion peak sales guidance Peak sales1 multi-billion USD per asset Select assets, by expected submission year of first indication CRM Immunology Neuroscience Oncology abelacimab 2027 ianalumab 2026 del-brax ≥2029 pelabresib 2026 FXI/FXIa inh. B-cell depleter BAFF-R i

  14. Slide 14: Strong in-market assets and robust pipeline underpin confidence in growth

    Taken together, our strong in-market assets and robust pipeline underpin our confidence in mid- and long-term growth Net sales 2026-2031 >2031 Illustrative, expected % CAGR cc1 +5% CAGR Mid-single digit +5-6% CAGR 2025-2030 Mid-single digit >2031 De-risked in-market brands2 1 2026-2031 +5% CAGR 2 Lo

  15. Slide 15: We expect to maintain our mid-single digit growth profile in the long-term

    We expect to maintain our mid-single digit growth profile in the long-term… Consensus1 sales Key drivers of mid-single digit growth in the long-term USD bn ~Gap to In-market Registration, Currently in / Internal 70.4 mid-single digit growth Phase III and II entering Phase I pipeline inflow Cosentyx

  16. Slide 16: Supported by in-market assets and a full pipeline

    …supported by in-market assets and a full pipeline In-market assets Potential high-value NMEs CRM Immunology Neuroscience Oncology Peak sales guidance issued1 3+ brands with potential additional upside 20+ assets in Registration, Phase III and II 10+ assets currently in / entering Phase I abelacimab

  17. Slide 17: We expect 35+ submission-enabling readouts through 2031

    We expect 35+ submission-enabling readouts through 2031… Select assets (expected) Readouts 2026 ianalumab 1L ITP Regulatory 2026 Pluvicto mHSPC approval (JP) Leqvio CVRR-LDLC (ORION-4) Studies with Cosentyx PMR approval (US) Rhapsido HS announced ianalumab SjD approval (US) positive readouts 2027 ab

  18. Slide 18: We continue to improve our R&D productivity

    …and we continue to improve our R&D productivity Biomedical Research End-to-end cycle time4 25 Median cycle time per phase (year) projects entered the +25% 9.1 BR portfolio1 in 2025 vs. 2022 Registration 0.7 ~20% 2.2 Phase III 3.2 years spent in lead optimization2 (2023–25) 1 year faster vs. 2020–22

  19. Slide 19: Cardiovascular-Renal-Metabolic therapeutic area pipeline

    Our Cardiovascular-Renal-Metabolic therapeutic area focuses on areas of high unmet need, with a strong mid- and late-stage pipeline Selected projects (MoA/indication) Pre-clinical Phase I Phase II Phase III Registration Next milestone / status CRM strategy Leqvio (PCSK9 siRNA; CVRR-LDLC, secondary •

  20. Slide 20: Abelacimab represents a multi-billion dollar opportunity, building on SPAF

    Abelacimab represents a multi-billion dollar opportunity, building on SPAF Unmet need in SPAF SPAF as lead indication • ~24m high-risk AF patients1; ~40% undertreated with anticoagulation • Ph III LILAC study interim analysis completed, trial progressing as planned due to bleeding risk2, facing high

  21. Slide 21: Expanding our siRNA and oligonucleotide leadership in CRM

    Expanding our siRNA and oligonucleotide leadership in CRM QCZ484 AGT siRNA, Q6M dosing | Hypertension Farabursen FiC oligonucleotide targeting miR17 | ADPKD Reduced SBP and DBP in Phase Ib participants with hypertension1 QCZ484 150 mg QCZ484 300 mg Pooled placebo ~12m people with ADPKD globally; ~50

  22. Slide 22: Our Immunology pipeline anchored by Rhapsido and ianalumab

    Our Immunology pipeline spans rheumatology, dermatology and allergy, anchored by Rhapsido and ianalumab Selected projects (MoA/indication) Pre-clinical Phase I Phase II Phase III Registration Next milestone / status Immunology strategy Cosentyx (IL-17A inhibitor; PMR) Approved Q4 2026 EU / US • Driv

  23. Slide 23: GHZ339 offers a multi-billion dollar opportunity in atopic dermatitis

    GHZ339 offers a multi-billion dollar opportunity as a potential first anti-IL-13/IL-18 bispecific for AtD, with positive Ph IIb data Significant unmet need in atopic dermatitis GHZ339 AtD Phase IIb data ~45% of patients on systemic therapy do not achieve adequate control, requiring deeper, more dura

  24. Slide 24: Advancing Rhapsido as a pipeline-in-a-pill

    Advancing Rhapsido as a pipeline-in-a-pill, with food allergy as a large upcoming opportunity Remibrutinib in food allergy Pipeline-in-a-drug potential Unmet need Compelling Phase II results CSU Approved in US, EU, CN and JP >3.5m high-risk • Superiority vs. placebo, dose-dependent effects patients

  25. Slide 25: Complementary assets broaden the Immunology opportunity

    Complementary assets broaden the Immunology opportunity Ianalumab | B-cell depleter & BAFF-R inhibitor GIA632 | High affinity IL-15 mAb Lead indication: SjD, under FDA review. LCM: SLE, LN, SSc, ITP. Anti-IL-15 inhibits T cell activation and IFN-γ release; validated target in vitiligo & celiac disea

  26. Slide 26: Our Neuroscience pipeline focuses on MS, neuromuscular and neurodegenerative diseases

    Our Neuroscience pipeline focuses on multiple sclerosis, neuromuscular and neurodegenerative diseases Selected projects (MoA/indication) Pre-clinical Phase I Phase II Phase III Registration Next milestone / status Neuroscience strategy Ph III studies positive, US submission Remibrutinib (BTK inhibit

  27. Slide 27: Del-brax has the potential to be the first approved drug for FSHD

    Del-brax has the potential to be the first approved drug for FSHD Phase I/II FORTITUDE study, biomarker cohort ~45-87k Plasma KHDC1L Primary endpoint Creatine kinase Key secondary endpoint FSHD patients in the US and EU. A progressive PBO (n=16) 24 mg/kg del-brax (total AOC weight, 2 mg/kg siRNA com

  28. Slide 28: We continue to progress on our DMD and Huntington's disease assets

    We continue to progress on our DMD and Huntington’s disease assets Del-zota for DMD44 Votoplam for Huntington’s disease >80% Dystrophin CK reduction % of normal vs baseline Change from baseline +25% -52.5% dystrophin increase difference of 10mg 5 mg/kg Q6W dose vs. matched natural history 50% normal

  29. Slide 29: Robust Oncology pipeline across breast, prostate and hematology

    Robust Oncology pipeline across breast, prostate and hematology, with multi-indication potential via RLT Selected projects (MoA/indication) Pre-clinical Phase I Phase II Phase III Registration Next milestone / status Oncology strategy ECI830 (CDK2i; also in other solid tumors)1 Advancing into Ph II

  30. Slide 30: Building on our legacy of leadership in MPNs with pelabresib

    Building on our legacy of leadership in MPNs with pelabresib Phase III MANIFEST-2 trial – 96 week data1 (144 week data oral at ASH 20262) Submitted in EU based on Phase III MANIFEST-2 100 Splenic responses PBO+RUX (N=216) sustained in a higher Active discussions with FDA on potential 90 PELA+RUX (N=

  31. Slide 31: Advancing the next wave of innovation in prostate and breast cancer

    Advancing the next wave of innovation in prostate and breast cancer Prostate cancer: Building on Pluvicto with 225Ac-PSMA-617 (AAA817), Breast cancer: Building on Kisqali with a portfolio spanning our next-generation RLT CDK inhibitors, pan-mutant PI3Kαi, RLT, and ADCs AcTION Phase I trial: Deep PSA

  32. Slide 32: Strengthening our RLT platform across targets, indications, isotopes and combinations

    Strengthening our RLT platform across targets, indications, isotopes and combinations Select clinical Broad platform potential PSMA SSTR FAP DLL3 HER2 trial programs 2 approved medicines expanding into earlier lines; Prostate cancer 7 assets in clinical trials NETs Deep preclinical pipeline, with 20

  33. Slide 33: Disciplined external innovation to strengthen our pipeline

    Continued high focus on strengthening our pipeline through disciplined external innovation Select examples1 Exploratory to preclinical Phase I Phase II Phase III CRM Immunology Neuroscience Oncology 2 and RLT Cross-TA and AI/ML 1. Select Corporate & Business Development Transactions announced since

  34. Slide 34: Scaling AI across the value chain to unlock productivity and performance

    Scaling AI across the value chain to unlock productivity and performance Our aspiration Increase probability Improve cycle times Accelerate sales Meaningfully increase of success (years) growth productivity ~8%1 → ~12% ~122 → ~8 Novartis priority AI & technology projects Target identification Digita

  35. Slide 35: AI is already supporting how we discover and develop medicines

    AI is already supporting how we discover and develop medicines… Select examples Research Development Multiple novel targets discovered with the help of AI, advancing 50% potentially more accurate enrollment forecasts in minutes, not weeks; toward our pipeline scaling to all studies in 2027 95% of sm

  36. Slide 36: AI in how we make, supply and bring medicines to patients

    …and increasingly how we make, supply and bring them to patients Select examples Manufacturing Commercial ~100% service levels for radioligand therapy deliveries, supported ~100% of US sales reps using AI to identify their next best action by AI-enabled logistics with customers ~90% faster US patien

  37. Slide 37: Recognized leadership across priority ESG measures

    Recognized leadership across priority ESG measures Rating Rating/ranking¹ Status 2026 recognitions Select examples Access to Medicine 1st place for second 1st Index (ATMI) consecutive time Named to Fortune’s 2026 Change the World List for our malaria program MSCI AAA ESG Leaders group Supporting mal

  38. Slide 38: Our strategy is delivering results

    Our strategy is Our growth profile We have a full pipeline delivering results remains attractive and strong capabilities • Delivered +8% cc sales CAGR • Growing in 2026 through our • Strong position in 4 core from 2020-20251,2 largest LoE impact therapeutic areas and advanced technology platforms •

  39. Slide 39: Appendix

    Appendix UW) NOVARTIS

  40. Slide 40: We are scaling AI across key priority areas in R&D

    We are scaling AI across key priority areas in R&D Early clinical Clinical planning Discovery Lead Op Preclinical Analytics Reg Post-approval development & operations Target Generative Translational Predictive Digital protocol Agentic clinical data Generative medical ID Chemistry AI compliance desig

  41. Slide 41: Abbreviations (1/2)

    Abbreviations (1/2) Abbreviation Full form Abbreviation Full form Abbreviation Full form Abbreviation Full form 1L First-line BET Bromodomain and Extra-Terminal cUHDRS Composite Unified Huntington's FPFV First Patient First Visit 2L Second-line BID Twice daily Disease Rating Scale FSHD Facioscapuloh

  42. Slide 42: Abbreviations (2/2)

    Abbreviations (2/2) Abbreviation Full form Abbreviation Full form Abbreviation Full form Abbreviation Full form IGA Investigator's Global Assessment MoA Mechanism of Action PMS Progressive Multiple Sclerosis siRNA Small Interfering RNA IgAN IgA Nephropathy mRNA Messenger RNA PPR Papulopustular Rosac

Novartis — Investor Presentation (November 2026) on 6ix